Overview
What it is.
AOD-9604 is a small fragment of the human growth hormone molecule, isolated for the segment researchers believed was responsible for fat-metabolism effects without triggering GH's broader growth-signaling activity.
Research Areas
- Studied for its potential role in fat-metabolism research
- Studied as an isolated fragment of the growth hormone molecule
- Studied in early-stage metabolic research trials
Batch & Testing
Proof, not promises.
COA ships with every order
Every batch we release is independently HPLC tested before it ever reaches a lab bench. Browse the full certificate library.
Research Deep-Dive
How it works.
Research Deep-Dive
How it works.
AOD-9604 is a 16-amino-acid fragment of the human growth hormone molecule, engineered to isolate the piece researchers believed was responsible for fat-metabolism (lipolytic) effects, without the broader growth-promoting activity of full-length growth hormone. It was developed by the Australian company Metabolic Pharmaceuticals specifically as an anti-obesity drug candidate.
AOD-9604 corresponds to the C-terminal fragment of human growth hormone (176-191), the region researchers identified as driving GH's effect on fat breakdown in animal models, theoretically without triggering GH's effects on bone and tissue growth or insulin resistance.
Use Cases Explored
- Historical drug-development research into isolated GH-fragment approaches to fat metabolism
- Academic and mechanistic study of lipolytic signaling separate from full GH activity
The Evidence
Early Phase 2 signal (12-week trial)
An earlier, smaller trial reported a modest weight-loss difference versus placebo (2.6 kg vs 0.8 kg) that generated initial optimism about the compound.
Pivotal Phase 2b trial (536 participants, reported 2007)
In the larger, 24-week OPTIONS trial with oral dosing, AOD-9604 failed to produce statistically significant weight loss versus placebo. Development for the obesity indication was terminated, and the company never advanced it to Phase 3 or published the negative results in a peer-reviewed journal.
Honest limits
Some researchers have suggested the oral delivery method — rather than the underlying biology — may explain the failure, since peptides generally degrade in the GI tract, but no large injectable trial was ever run to test that. AOD-9604 has never received FDA approval as a drug for any indication and has no legitimate U.S. compounding pathway.
Specifications
The essentials.
Specifications
The essentials.
- Vial Capacity
- 3 ml glass vial
- Form
- Lyophilized powder
- Solubility
- Reconstitute with bacteriostatic water
- Storage
- Store in a cool, dry place. Refrigerate at 2–8°C after reconstitution
- Shelf Life
- 24 months lyophilized; 4–6 weeks refrigerated after reconstitution
Metabolic
AOD-9604
hGH Fragment 176-191
A growth-hormone fragment studied for a role in fat-metabolism research.
Size
COA-backed guarantee — independently test any vial; if it's under 99% purity, full refund + testing costs covered.
All products sold by One Tap Peptides are intended for laboratory research use only. Not for human consumption. Not intended for animal use. Not intended for diagnostic or therapeutic purposes.
Related
